Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors

ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (Nasdaq:ACOR)
today announced that Catherine D. Strader, Ph.D., has joined its board
of directors, effective February 17. Dr. Strader is currently a founding
partner at Synergy Partners R&D Solutions.

“I am delighted to welcome Dr. Strader to Acorda’s board of directors,”
said Ron Cohen, M.D., Acorda’s President and CEO. “Catherine brings
decades of experience as both a drug developer and biopharmaceutical
business executive with an outstanding track record of achievement. I
expect her to add significant value to the Board and the Company as we
continue to develop our pipeline and grow our business.”

“I am excited to be joining Acorda’s board of directors,” said Dr.
Strader. “The Company has a promising pipeline of innovative
neurological therapies. I’m looking forward to working with Ron, the
Board and the management team to help advance these programs.”

Dr. Strader will be filling a newly-added Board seat and will be up for
re-election in 2018.

Prior to founding Synergy Partners R&D Solutions, Dr. Strader held
executive leadership positions at both Merck, where she was Vice
President and Site Head, and Schering-Plough, where she was Executive
Vice President of Discovery Research and Chief Scientific Officer. She
has guided more than 50 compounds through drug discovery and development
during her career. At Merck, she led an external research initiative,
with responsibility for developing and implementing an integrated
strategy for building Merck’s early pipeline using external sources of
innovation.

At Schering-Plough, Dr. Strader had both strategic and operational
responsibility for the company’s global small molecule and biologics
discovery research portfolio, when she and her team initiated many of
the programs that currently populate the Merck portfolio.

Dr. Strader received her B.S. in Chemistry from the University of
Virginia and her Ph.D. in Chemistry from the California Institute of
Technology. She did her postdoctoral training as a Howard Hughes Fellow
in Robert Lefkowitz’s laboratory at Duke University and is the author of
more than 150 scientific publications.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused
on developing therapies that restore function and improve the lives of
people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies
addressing a range of disorders, including Parkinson’s disease, migraine
and multiple sclerosis. Acorda markets three FDA-approved therapies,
including AMPYRA^® (dalfampridine) Extended Release Tablets,
10 mg.

For more information, please visit the Company’s website at: www.acorda.com.

Forward-Looking Statement

This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management’s
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: the
ability to realize the benefits anticipated from the Biotie and Civitas
transactions, among other reasons because acquired development programs
are generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to acquired
programs generally improves over time; the ability to successfully
integrate Biotie’s operations and Civitas’ operations, respectively,
into our operations; we may need to raise additional funds to finance
our expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell Ampyra
(dalfampridine) Extended Release Tablets, 10 mg in the U.S.; third party
payers (including governmental agencies) may not reimburse for the use
of Ampyra or our other products at acceptable rates or at all and may
impose restrictive prior authorization requirements that limit or block
prescriptions; the risk of unfavorable results from future studies of
Ampyra or from our other research and development programs, including
CVT-301 or any other acquired or in-licensed programs; we may not be
able to complete development of, obtain regulatory approval for, or
successfully market CVT-301, any other products under development, or
the products that we will acquire when we complete the Biotie
transaction; the occurrence of adverse safety events with our products;
delays in obtaining or failure to obtain and maintain regulatory
approval of or to successfully market Fampyra outside of the U.S. and
our dependence on our collaborator Biogen in connection therewith;
competition; failure to protect our intellectual property, to defend
against the intellectual property claims of others or to obtain third
party intellectual property licenses needed for the commercialization of
our products; and failure to comply with regulatory requirements could
result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this press release are made only as
of the date hereof, and we disclaim any intent or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170221005593/en/